Does HRT Increase Breast Cancer Risk?
When it comes to HRT and breast cancer risk, there’s no single yes-or-no answer. The best-known randomized evidence on HRT and breast cancer risk comes from the Women’s Health Initiative (WHI), which showed two different patterns:
- Estrogen alone: Among women who’d had a hysterectomy, conjugated equine estrogen was associated with lower breast cancer incidence and mortality than placebo (Chlebowski et al., 2020).
- Estrogen plus progestin: Among women with a uterus, conjugated equine estrogen plus medroxyprogesterone acetate was associated with higher breast cancer incidence (Chlebowski et al., 2020).
That doesn’t mean estrogen always protects against breast cancer. Risk varies with the hormone regimen, duration of treatment, age, and medical history (The North American Menopause Society [NAMS], 2022).
What Did the WHI Find About HRT and Breast Cancer Risk?
The WHI ran two separate randomized hormone therapy trials:
- Estrogen plus progestin (16,608 women with a uterus): The trial was stopped early in 2002 after about five years. Long-term follow-up showed breast cancer incidence of 0.45% per year vs. 0.36% with placebo, a 28% relative increase (Chlebowski et al., 2020).
- Estrogen alone (10,739 women with a prior hysterectomy): Breast cancer incidence was 0.30% per year vs. 0.37% with placebo, and breast cancer mortality was lower too (Chlebowski et al., 2020).
These findings apply to the formulations and populations studied in the WHI. They don’t mean all forms of hormone therapy produce identical results.
Why Do Other Studies Give Different Answers?
This is where discussions about HRT and breast cancer risk can become confusing. A large 2019 analysis of observational studies found increased breast cancer risk with most types of systemic menopausal hormone therapy. The increase was greater with estrogen-progestogen therapy than with estrogen alone, and it grew with longer use (Collaborative Group on Hormonal Factors in Breast Cancer, 2019).
The studies were designed differently. The WHI tested specific medications in defined patient groups, while observational studies follow women using a wider range of formulations and durations. That’s why no single study supports a blanket statement like “estrogen causes breast cancer” or “estrogen prevents breast cancer.”
Does the Type of HRT Change Breast Cancer Risk?
Yes. Women with a uterus generally need a progestogen alongside systemic estrogen to protect the uterine lining. Women who’ve had a hysterectomy may be able to use estrogen alone (NAMS, 2022).
Modern therapy also includes options the WHI didn’t test, including transdermal estradiol and micronized progesterone. Current evidence doesn’t justify assuming every modern HRT regimen carries the same risks as the WHI combinations (NAMS, 2022).
What About the FDA’s HRT Warning?
In November 2025, the FDA began requesting changes to the boxed warnings on menopausal hormone therapy products. In February 2026, it approved updated labeling for an initial group of products, removing boxed-warning statements about breast cancer, cardiovascular disease, and probable dementia (U.S. Food and Drug Administration [FDA], 2026).
This doesn’t mean HRT has no risks. The changes are meant to support individualized decisions instead of applying the original WHI warnings to every product (FDA, 2026).
Who Should Be More Cautious About HRT?
Your clinician should review factors such as:
- Personal history of breast or endometrial cancer
- Family history of breast cancer
- Whether you still have a uterus
- Previous blood clots, stroke, or cardiovascular disease
- Age and time since menopause
- Type, dose, route, and expected duration of hormone therapy
Systemic hormone therapy generally isn’t recommended for women with a history of breast cancer unless a specialist is involved. For otherwise healthy women with bothersome menopausal symptoms, major guidelines emphasize individualized decision-making (NAMS, 2022).
So, Does HRT Increase Breast Cancer Risk?
Some hormone therapy regimens are associated with increased breast cancer risk, while the risk appears different with estrogen-only therapy (Chlebowski et al., 2020; Collaborative Group on Hormonal Factors in Breast Cancer, 2019). There isn’t enough evidence to claim that all estrogen therapy either causes or prevents breast cancer.
That’s why the decision should be based on your symptoms, medical history, uterus status, treatment goals, and the specific therapy being considered (NAMS, 2022).
Making an HRT Decision at Androgenix
If hot flashes, night sweats, or sleep disruption are affecting your quality of life, a headline from more than 20 years ago shouldn’t be the only thing driving your decision.
At Androgenix in North Palm Beach, we review your symptoms, medical and family history, current screening, and treatment goals before discussing whether hormone therapy may be appropriate. Our goal is to help you understand the benefits and risks clearly enough to make an informed decision.
Learn more about the benefits of estrogen therapy.
Have questions about HRT and your individual breast cancer risk? Schedule a consultation with Androgenix in North Palm Beach to discuss your options.
Frequently Asked Questions About HRT and Breast Cancer Risk
Does estrogen cause breast cancer?
There’s no simple yes-or-no answer. In the WHI, women with a prior hysterectomy who took estrogen alone had fewer breast cancer diagnoses than those on placebo (Chlebowski et al., 2020). Observational studies have found increased risk with some forms and durations of estrogen therapy (Collaborative Group on Hormonal Factors in Breast Cancer, 2019).
Does HRT increase breast cancer risk?
Some types can. In the WHI, estrogen plus medroxyprogesterone acetate was associated with higher breast cancer incidence, while estrogen alone was associated with lower incidence among women with a prior hysterectomy (Chlebowski et al., 2020).
Did the FDA remove the boxed warning on HRT?
For several products, yes. Since November 2025, the FDA has been removing boxed-warning language about breast cancer, cardiovascular disease, and probable dementia. The boxed warning for endometrial cancer remains on systemic estrogen-only products for women with a uterus (FDA, 2026). HRT still isn’t risk-free, so discuss the labeled risks with your clinician.
Medical Disclaimer
This article is for educational purposes only and doesn’t replace individualized medical advice, diagnosis, or treatment. Discuss your medical history and treatment options with a qualified healthcare professional.
